MIRM - Mirum Pharmaceuticals GAAP EPS of -$1.02 beats by $0.05 revenue of $18.78M misses by $2.03M
- Mirum Pharmaceuticals press release ( NASDAQ: MIRM ): Q3 GAAP EPS of -$1.02 beats by $0.05 .
- Revenue of $18.78M (+275.6% Y/Y) misses by $2.03M .
- As of September 30, 2022, Mirum had cash, cash equivalents, restricted cash equivalents and investments of $285.3M.
- Mirum raises 2022 full year net product sales guidance estimate for LIVMARLI to $70M.
For further details see:
Mirum Pharmaceuticals GAAP EPS of -$1.02 beats by $0.05, revenue of $18.78M misses by $2.03M